



Outthink. Outperform.

## Weak start to the year

BAT's 1Q17 core earnings decreased by 31.4% yoy to RM120.4m, coming in below our and consensus expectations. Domestic volume continued to decline as consumer demand shifts to illegal cigarettes. We cut earnings as we assume legal industry volume would drop by 10% yoy in FY17 and remain flat in FY18-19. Recall that BAT may see cost savings from 2H17 onwards from sourcing tobacco products regionally. Maintain HOLD with lower TP of RM43.50.

### 1Q17 earnings below expectations

BAT recorded a decline of 1Q17 revenue by 24.5% yoy to RM770.7m due to the group's domestic volume decline of 23.0% yoy. Stripping out one-off restructuring expenses due to the winding down of the factory of RM1.6m, core net profit decreased by 31.4% yoy to RM120.4m, coming in below our and consensus expectations at 16.7% and 16.4% of forecasts respectively. The group declared a 1st interim DPS of 40 sen (vs. 1Q16:55sen).

### Losing market share due to shift in demand to illegal cigarettes

The decline in volume was largely due to a spike in demand for illegal cigarettes from 54.3% in October 2016 to a high of 57.1% in December 2016. This caused BAT's market share within the legal industry to drop to 53.5% (vs. 54.3% in 4Q16 and 57.1% in FY16) as consumers continued to switch to illegal cigarettes which are cheaper alternatives. Premium brand leader Dunhill registered a drop of 1.3 ppts qoq to 37.3% in February 2017 whereas aspirational premium brands Peter Stuyvesant and Pall Mall recorded a total market share of 12.1%, higher than 11.5% in 4Q16.

### Maintain HOLD with lower DDM-derived TP of RM43.50

We tweak our assumptions post the release of BAT's final 2016 accounts and cut our forecasts by 8-11% for FY17-19, mainly by estimating legal industry volume to drop by 10% yoy in FY17 and stay flat in FY18-19 (previously forecasting a recovery of 1-6% from the low FY16 base). Recall that BAT is currently restructuring its business operations by sourcing tobacco products from other BAT factories regionally such as Indonesia, Singapore and Korea, which should bring about cost savings, and these business transformations are targeted to be completed by 2H17. We maintain our HOLD rating with a lower 12-month DDM-derived TP of RM43.50 (from RM46.90). Dividend yields of about 5% in FY17-19E should be supportive of the share price. Key upside risks include stronger-than-expected sales volume growth and lower-than-expected operating expenses whereas a key downside risk includes excise hikes which would lead to price increases and industry volume declines.

### Earnings & Valuation Summary

FYE Dec	2015	2016	2017E	2018E	2019E
Revenue (RMm)	4581.5	3756.4	3485.2	3485.2	3485.2
EBITDA (RMm)	1277.3	929.6	879.9	897.4	907.8
Pretax profit (RMm)	1231.0	908.5	872.6	889.2	898.4
Net profit (RMm)	910.1	721.3	664.1	676.7	683.7
EPS (sen)	318.7	236.4	232.6	237.0	239.5
PER (x)	14.8	19.9	20.2	19.9	19.7
Core net profit (RMm)	910.1	675.1	664.1	676.7	683.7
Core EPS (sen)	318.7	236.4	232.6	237.0	239.5
Core EPS growth (%)	0.9	(25.8)	(1.6)	1.9	1.0
Core PER (x)	14.8	19.9	20.2	19.9	19.7
Net DPS (sen)	312.0	278.0	231.0	235.0	238.0
Dividend Yield (%)	6.6	5.9	4.9	5.0	5.1
EV/EBITDA (x)	10.7	14.6	15.4	15.0	14.9
Chg in EPS (%)			-8.1	-10.5	-10.2
Affin/Consensus (x)			0.9	0.9	0.9

Source: Company, Affin Hwang estimates

## Results Note

# British American Tobacco

ROTH MK  
Sector: Consumer

RM47.06 @ 20 Apr 2017

HOLD (maintain)

Downside 7.6%

Price Target: RM43.50

Previous Target: RM46.90



## Price Performance

	1M	3M	12M
Absolute	-1.3%	+7.7%	-11.8%
Rel to KLCI	-1.0%	+2.9%	-13.5%

## Stock Data

Issued shares (m)	285.5
Mkt cap (RMm)/(US\$m)	13,437/3,053.5
Avg daily vol - 6mth (m)	0.3
52-wk range (RM)	40.3-55.6
Est free float	40.9%
BV per share (RM)	2.15
P/BV (x)	21.91
Net cash/ (debt) (RMm) (1Q17)	(330.0)
ROE (2017E)	107%
Derivatives	Nil
Shariah Compliant	No

## Key Shareholders

British American Tobacco	50.0%
Aberdeen	7.1%
EPF	5.9%

Source: Affin Hwang, Bloomberg

Yap Po Leen  
(603) 2146 7547  
[poleen.yap@affinhwang.com](mailto:poleen.yap@affinhwang.com)

## Securities

AFFIN HWANG  
CAPITAL

Outthink. Outperform.

Fig 1: Results comparison

FYE Dec (RMm)	1Q17	QoQ % chg	YoY % chg	Comments
Revenue	770.7	(8.3)	(24.5)	1Q17 revenue decline mainly due to volume decline of 23% yoy due to shift in demand to illicit cigarettes, which are cheaper alternatives
Op costs	(613.0)	57.4	(21.1)	
EBITDA	157.7	(65.0)	(35.5)	
<i>EBITDA margin</i>	20.5	(33.2)	(3.5)	
Depr & Amort	(1.4)	(38.3)	(84.9)	
EBIT	156.3	(65.2)	(33.5)	
<i>EBIT margin (%)</i>	20.3	(33.1)	(2.7)	Contraction due to escalating cost pressure.
Int expense	(1.5)	>100	(62.7)	
Int and other inc	0.0	0.0	0.0	
Associates	0.0	0.0	0.0	
Exceptional items	1.6	n.m.	n.m.	One-off restructuring expenses in 1Q17 due to the winding down of the factory.
-Project costs	0.4			
-Storage and transfer of raw materials	0.7			
-Change management costs	0.5			
<b>Pretax</b>	<b>156.4</b>	(50.6)	(32.3)	
Tax	(37.6)	38.4	(32.4)	
<i>Tax rate (%)</i>	24.0	15.5	(0.0)	
MI	0.0	0.0	0.0	
<b>Net profit</b>	<b>118.8</b>	(58.9)	(32.3)	
EPS (sen)	41.6	(58.9)	(32.3)	
<b>Core net profit</b>	<b>120.4</b>	<b>(23.5)</b>	<b>(31.4)</b>	Below expectations.

Source: Affin Hwang, Company data

#### Equity Rating Structure and Definitions

<b>BUY</b>	Total return is expected to exceed +10% over a 12-month period
<b>HOLD</b>	Total return is expected to be between -5% and +10% over a 12-month period
<b>SELL</b>	Total return is expected to be below -5% over a 12-month period
<b>NOT RATED</b>	Affin Hwang Investment Bank Berhad does not provide research coverage or rating for this company. Report is intended as information only and not as a recommendation

*The total expected return is defined as the percentage upside/downside to our target price plus the net dividend yield over the next 12 months.*

<b>OVERWEIGHT</b>	Industry, as defined by the analyst's coverage universe, is expected to outperform the KLCI benchmark over the next 12 months
<b>NEUTRAL</b>	Industry, as defined by the analyst's coverage universe, is expected to perform inline with the KLCI benchmark over the next 12 months
<b>UNDERWEIGHT</b>	Industry, as defined by the analyst's coverage universe is expected to under-perform the KLCI benchmark over the next 12 months

This report is intended for information purposes only and has been prepared by Affin Hwang Investment Bank Berhad (14389-U) ("the Company") based on sources believed to be reliable. However, such sources have not been independently verified by the Company, and as such the Company does not give any guarantee, representation or warranty (express or implied) as to the adequacy, accuracy, reliability or completeness of the information and/or opinion provided or rendered in this report. Facts, information, views and/or opinion presented in this report have not been reviewed by, may not reflect information known to, and may present a differing view expressed by other business units within the Company, including investment banking personnel. Reports issued by the Company, are prepared in accordance with the Company's policies for managing conflicts of interest arising as a result of publication and distribution of investment research reports. Under no circumstances shall the Company, its associates and/or any person related to it be liable in any manner whatsoever for any consequences (including but are not limited to any direct, indirect or consequential losses, loss of profit and damages) arising from the use of or reliance on the information and/or opinion provided or rendered in this report. Any opinions or estimates in this report are that of the Company, as of this date and subject to change without prior notice. Under no circumstances shall this report be construed as an offer to sell or a solicitation of an offer to buy any securities. The Company and/or any of its directors and/or employees may have an interest in the securities mentioned therein. The Company may also make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

Comments and recommendations stated here rely on the individual opinions of the ones providing these comments and recommendations. These opinions may not fit to your financial status, risk and return preferences and hence an independent evaluation is essential. Investors are advised to independently evaluate particular investments and strategies and to seek independent financial, legal and other advice on the information and/or opinion contained in this report before investing or participating in any of the securities or investment strategies or transactions discussed in this report.

Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data.

The Company's research, or any portion thereof may not be reprinted, sold or redistributed without the consent of the Company.

The Company, is a participant of the Capital Market Development Fund-Bursa Research Scheme, and will receive compensation for the participation.

This report is printed and published by:  
Affin Hwang Investment Bank Berhad (14389-U)  
A Participating Organisation of Bursa Malaysia Securities Berhad

22nd Floor, Menara Boustead,  
69, Jalan Raja Chulan,  
50200 Kuala Lumpur, Malaysia.

T : + 603 2146 3700  
F : + 603 2146 7630  
research@affinhwang.com

www.affinhwang.com